Testing AI-guided virtual reality rehabilitation at home after stroke
Tests an AI-guided virtual reality system for home rehabilitation in adults recovering from stroke.
Plain-language title generated from the registry record
Registry title: Integrating AI in Stroke Neurorehabilitation
Key facts
- Where
- Cluj-Napoca, RomaniaSee the site
Where in Romania
- UMFCluj-Napoca, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eodyne Systems SL
- Trial code
- NCT07138495
- Record updated
- 22 December 2025
- Original description
The AISN multicenter randomized controlled trial will assess the effectiveness of a novel artificial intelligence (AI)-based clinical decision-support system integrated into the Rehabilitation Gaming System (RGS) for home-based post-stroke rehabilitation. Approximately 192 participants ≥6 months post-stroke will be recruited across several European centers and assigned to one of three groups: RGS with AI decision support, RGS without AI, or standard care. The primary outcome is upper limb motor improvement for stroke patients, with secondary measures including cognitive function, independence, quality of life, usability, cost-effectiveness, and AI-based support performance.Read full original descriptionShow less
Integrating AI in Stroke Neurorehabilitation (AISN)
The AISN multicenter randomized controlled trial will assess the effectiveness of a novel artificial intelligence (AI)-based clinical decision-support system integrated into the Rehabilitation Gaming System (RGS) for home-based post-stroke rehabilitation. Approximately 192 participants ≥6 months post-stroke will be recruited across several European centers and assigned to one of three groups: RGS with AI decision support, RGS without AI, or standard care. The primary outcome is upper limb motor improvement for stroke patients, with secondary measures including cognitive function, independence, quality of life, usability, cost-effectiveness, and AI-based support performance.
Inclusion: ≥ 6 months post-stroke; Patients presenting a first-ever ischemic or intracerebral hemorrhagic stroke; Mild to Moderate unilateral upper limb motor impairment: Medical Research Council proximal and distal upper limb MRC ≥2; Action Research Arm Test: ARAT score < 50 (0 = no function, 57 = no functional limitation); Age > 18 years old; Able to sit on a chair or a wheelchair and interact with RGS during an entire session; Minimal experience with smartphone technology based on the clinician's opinion; Willing to participate in the RGS therapy; Sign the Informed Consent Form.
Exclusion: Diagnosis with Epilepsy; Severe associated impairment such as proximal but not distal spasticity, communication disabilities (sensory, Wernicke aphasia or apraxia), major pain (VAS > 75-100 mm), orthopedic devices that would interfere with the correct execution of the experiment (Modified Ashworth Scale > 3); Severe cognitive capabilities preventing the execution of the experiment or according to clinicians' criteria; Unable to use the RGS app independently according to the clinician's observations and lacking support from a caregiver to use the RGS app; No experience with smartphone technology or based on the clinician's opinion; Refusal to sign the Informed Consent; Participating or planning to participate in another trial while being part of the present study.